Certain NSCLC Subgroups May Not Benefit From Immunotherapy Certain NSCLC Subgroups May Not Benefit From Immunotherapy
A comprehensive study exploring NSCLC subgroup responses to immunotherapy may help determine which patients are less likely to benefit from these agents.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 16, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
FDA approves repotrectinib for ROS1-positive non-small cell lung cancer
On November 15, 2023, the Food and Drug Administration approved repotrectinib (Augtyro, Bristol-Myers Squibb Company) for locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - November 16, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Osimertinib + Chemo Improves Progression-Free Survival in Advanced NSCLC
THURSDAY, Nov. 16, 2023 -- For patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC), osimertinib with chemotherapy leads to significantly longer progression-free survival (PFS) compared with osimertinib alone, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 16, 2023 Category: Pharmaceuticals Source Type: news
FDA OKs New Option for Advanced ROS1-Positive Lung Cancer
(MedPage Today) -- The FDA approved repotrectinib (Augtyro) -- an oral tyrosine kinase inhibitor (TKI) targeting ROS1 oncogenic fusions -- for the treatment of locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC)... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - November 16, 2023 Category: American Health Source Type: news
FDA Approves Augtyro (repotrectinib) for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer (NSCLC)
PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Augtyro (repotrectinib) for the treatment of adult patients with locally advanced or metastatic... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 16, 2023 Category: Drugs & Pharmacology Source Type: news
Non-Small Cell Lung Cancer Highlights From ESMO 2023 Non-Small Cell Lung Cancer Highlights From ESMO 2023
Key studies on non –small cell lung cancer presented at ESMO 2023 include strong practice-changing results from the PAPILLON, LIBRETTO, and MARIPOSA trials, as discussed by Dr Enriqueta Felipe.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 14, 2023 Category: Consumer Health News Tags: None ReCAP Source Type: news
Roche ’s subcutaneous injection of Tecentriq recommended by the EU’s CHMP for multiple cancer types
If approved, Tecentriq subcutaneous (SC) would be the first injectable PD-(L)1 cancer immunotherapy in the EU, cutting treatment time by approx. 80%1 The CHMP recommended Tecentriq SC for all indications of intravenous (IV) Tecentriq, including certain types of lung, liver, bladder and breast cancer2A majority of healthcare professionals surveyed in the IMscin001 study found that the SC formulation is easy to administer and could save time compared with IV1Basel, 14 November 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency ’s Committee for Medicinal Products for Human Use (C...
Source: Roche Investor Update - November 14, 2023 Category: Pharmaceuticals Source Type: news
Roche ’s subcutaneous injection of Tecentriq recommended by the EU’s CHMP for multiple cancer types
If approved, Tecentriq subcutaneous (SC) would be the first injectable PD-(L)1 cancer immunotherapy in the EU, cutting treatment time by approx. 80%1 The CHMP recommended Tecentriq SC for all indications of intravenous (IV) Tecentriq, including certain types of lung, liver, bladder and breast cancer2A majority of healthcare professionals surveyed in the IMscin001 study found that the SC formulation is easy to administer and could save time compared with IV1Basel, 14 November 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency ’s Committee for Medicinal Products for Human Use (C...
Source: Roche Media News - November 14, 2023 Category: Pharmaceuticals Source Type: news
ESMO 2023: Reflecting on New Data in Advanced NSCLC ESMO 2023: Reflecting on New Data in Advanced NSCLC
Julia Rotow, MD, analyzes the latest research presented at ESMO that could impact patient care going forward.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 13, 2023 Category: Consumer Health News Tags: None MDAngle Source Type: news
Road to RSNA 2023: CT
Photon-counting CT (PCCT) has dominated discussion for the last number of RSNA meetings, and this year will be no exception. Expect to hear PCCT research findings about how the technology can increase image quality and lower radiation dose in pulmonary angiography for the diagnosis of pulmonary embolism; how it appears to boost the contrast-to-noise ratio of vascular structures on chest CT; and what it has to offer in the musculoskeletal arena.
Meeting attendees will also get the scoop on the role CT radiomics can play in clinical care, particularly helping clinicians determine the best treatment for patients sufferi...
Source: AuntMinnie.com Headlines - November 13, 2023 Category: Radiology Authors: Kate Madden Yee Tags: 2023 2023 CT Preview Source Type: news
CT-based deep learning radiomics may help determine NSCLC treatment
Thursday, November 30 | 11:10 a.m.-11:20 a.m. | R4-SSCH10-2 | Room S405 A CT-based deep-learning radiomics biomarker appears to characterize the level of expression of programmed cell death ligand 1 (PD-L1) in non-small cell lung cancers (NSCLCs), according to study results that will be presented Thursday morning.The findings could help clinicians set treatment for lung cancer patients, since tumors that express 50% or greater levels of PD-L1 tend to respond well to immunotherapy, wrote a team led by Jingshan Gong, MD, of Shenzhen Second People's Hospital in China.The study included 259 patients with pathology-confirmed ...
Source: AuntMinnie.com Headlines - November 13, 2023 Category: Radiology Authors: Kate Madden Yee Tags: 2023 CT Preview Source Type: news
TLS in Tumors May Predict Immunotherapy Benefit in NSCLC TLS in Tumors May Predict Immunotherapy Benefit in NSCLC
New data indicate that tertiary lymphoid structures could predict which patients with advanced non-small cell lung cancer will benefit most from immunotherapy.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 10, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Examination Procedure
SAN DIEGO, Calif. and ZUG, Switzerland, Nov. 10, 2023 -- (Healthcare Sales & Marketing Network) -- Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced that following a re-examination procedure, the Comp... Biopharmaceuticals, Oncology, Regulatory Mirati Therapeutics, KRAZATI, adagrasib, Non-Small Cell Lung Cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 10, 2023 Category: Pharmaceuticals Source Type: news
Selpercatinib Extends PFS in First-line RET-Positive NSCLC Selpercatinib Extends PFS in First-line RET-Positive NSCLC
A randomized trial found that selpercatinib improved PFS by more than two-fold, but overall survival data remain immature.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 6, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Galvanize Therapeutics Announces Promising Data on the Aliya ™ Pulsed Electric Field (PEF) System in Early-Stage Non-Small Cell Lung Cancer
SAN DIEGO, Nov. 6, 2023 /PRNewswire/ -- Galvanize Therapeutics, Inc., a leader in developing pulsed electric field therapies, unveiled compelling data from the INCITE-ES clinical study at the recent Society for Immunotherapy for Cancer (SITC) conference. The study evaluated the ability of... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 6, 2023 Category: Pharmaceuticals Tags: TRI Source Type: news
